Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 20, 2017
What is the competitive landscape for JANSSEN PHARMS, and when can generic versions of JANSSEN PHARMS drugs launch?
JANSSEN PHARMS has fifty-six approved drugs.| Patents: | 37 |
| Tradenames: | 54 |
| Ingredients: | 34 |
| NDAs: | 56 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
canagliflozin | Tablets | 100 mg and 300 mg | INVOKANA | 3/29/2017 |
canagliflozin andmetforminhydrochloride | Tablets | 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg | INVOKAMET | 3/29/2017 |
rivaroxaban | Tablets | 10 mg, 15 mg, and 20 mg | XARELTO | 7/1/2015 |
itraconazole | Oral Solution | 10 mg/mL | SPORANOX | 5/3/2013 |
levofloxacin | Oral Solution | 25 mg/mL | LEVAQUIN | 7/30/2009 |
norelgestromin and ethinyl estradiol | Transdermal System | 0.15 mg/0.02 mg per 24 hours | ORTHO EVRA | 3/22/2007 |
galantamine hydrobromide | Extended-release Capsules | 16 mg and 24 mg | RAZADYNE ER | 3/11/2006 |
galantamine hydrobromide | Extended-release Capsules | 8 mg | RAZADYNE ER | 3/2/2006 |
almotriptan malate | Tablets | 6.25 mg and 12.5 mg | AXERT | 12/8/2005 |
topiramate | Tablets | 50 mg | TOPAMAX | 9/8/2005 |
topiramate | Capsules | 15 mg and 25 mg | TOPAMAX SPRINKLE | 9/7/2005 |
methylphenidate hydrochloride | Extended-release Tablets | 18 mg*, 27 mg, 36 mg and 54 mg | CONCERTA | 7/19/2005 |
metformin hydrochloride | Extended-release Tablets | 18 mg, 27 mg, 36 mg and 54 mg | CONCERTA | 7/19/2005 |
risperidone | Orally Disintegrating Tablets | 0.25 mg | RISPERDAL | 4/11/2005 |
risperidone | Orally Disintegrating Tablets | 3 mg and 4 mg | RISPERDAL | 3/23/2005 |
galantamine hydrobromide | Tablets | 4 mg, 8 mg and 12 mg | RAZADYNE | 2/28/2005 |
topiramate | Tablets | 25 mg, 100 mg and 200 mg | TOPAMAX | 12/26/2001 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,696,091 | Pharmaceutical composition of topiramate | ► Subscribe | |||||||||||||||||||||||||||
| 8,323,691 | Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms | ► Subscribe | |||||||||||||||||||||||||||
| 7,576,111 | Substituted oxazolidinones and their use in the field of blood coagulation | ► Subscribe | |||||||||||||||||||||||||||
| 7,935,674 | Indole derivatives | ► Subscribe | |||||||||||||||||||||||||||
| 7,511,021 | Substituted indazole-O-glucosides | ► Subscribe | |||||||||||||||||||||||||||
| 6,905,654 | Method and apparatus for reducing static charges during polymerization of olefin polymers | ► Subscribe | |||||||||||||||||||||||||||
| 7,511,022 | Substituted indole-O-glucosides | ► Subscribe | |||||||||||||||||||||||||||
| 6,110,503 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent | ► Subscribe | |||||||||||||||||||||||||||
| 6,809,107 | Neurotrophic pyrrolidines and piperidines, and related compositions and methods | ► Subscribe | |||||||||||||||||||||||||||
| 8,936,810 | Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norway | 333360 | ► Subscribe | |||||||||||||||||||||||||||
| Taiwan | 200529859 | ► Subscribe | |||||||||||||||||||||||||||
| Poland | 330431 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 2300845 | ► Subscribe | |||||||||||||||||||||||||||
| World Intellectual Property Organization (WIPO) | 0191720 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 2259481 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 5133495 | ► Subscribe | |||||||||||||||||||||||||||
| Taiwan | 200422299 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2534024 | ► Subscribe | |||||||||||||||||||||||||||
| Austria | 318605 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2008018,C1261606 | Lithuania | ► Subscribe | PRODUCT NAME: RIVAROXABANUM; REGISTRATION NO/DATE: EU/1/07/472/001 - EU/1/08/472/008, 0080930 | ||||||||||||||||||||||||||
| 497 | Luxembourg | ► Subscribe | 91497, EXPIRES: 20230930 | ||||||||||||||||||||||||||
| C/GB07/065 | United Kingdom | ► Subscribe | PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021 | ||||||||||||||||||||||||||
| 2014 00016 | Denmark | ► Subscribe | PRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831 | ||||||||||||||||||||||||||
| 0670 | Netherlands | ► Subscribe | PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131119 | ||||||||||||||||||||||||||
| 6 | Finland | ► Subscribe | |||||||||||||||||||||||||||
| 2014000024 | Germany | ► Subscribe | PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831 | ||||||||||||||||||||||||||
| 0814 | Netherlands | ► Subscribe | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 | ||||||||||||||||||||||||||
| 00521 | Netherlands | ► Subscribe | PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006 | ||||||||||||||||||||||||||
| C0001 | France | ► Subscribe | PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,690 others who get our Drug Patent Expiration Alerts:
